arrow
Á

Ángel L. Guerrero

Hospital Clínico Universitario de Valladolid
H指数:33
被引数:4,488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study

评估抗CGRP单克隆抗体在偏头痛和自身免疫性疾病患者中的有效性与安全性:IMMUNO-CGRP研究

IF0
2026-04-010
OAAI
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response

阿托格匹兰坦在抗CGRP单克隆抗体治疗失败的偏头痛患者中的应用:一项关于疗效、安全性、持续性和应答预测因子的多中心真实世界研究

2025-11-280
OAAI
SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials

SAFE-CGRP研究:多中心回顾性评估在排除具有相关合并症或状况的受试者后,靶向CGRP通路的单克隆抗体在偏头痛中的安全性。

2025-11-270
OAAI
COVID-19 Vaccination Modifies COVID-19-Related Headache Phenotype: Evidence from Case–Control Study on 309 Participants

COVID-19疫苗接种改变了COVID-19相关头痛表型:来自309名参与者病例对照研究的证据

2025-11-270
OAAI
Redefining therapeutics in vATTR: Evaluation of response predictors to tafamidis and patisiran treatment in a non-endemic area. A proposal for a novel individualised therapeutic approach

重新定义vATTR中的治疗学:在非流行地区评估tafamidis和patisiran治疗反应预测因子。一项针对新型个体化治疗方法的建议。

2025-10-110
OAAI
Factors associated to the presence of headache in patients with influenza infection and its consequences: a 2010-2020 surveillance-based study
2024-02-082
OAAI
Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
2023-11-223
OAAI